

14th February, 2020

To,
The General Manager
Department of Corporate Services - CRD
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai 400 001

Dear Sir,

Sub: Outcome of Board Meeting – Quarterly Results

Dear Sir,

Further to our letter dated 4th February, 2020, we would like to inform that the Board of Directors of the Company at its meeting held today ie; 14th February, 2020 at 07.15 P.M and concluded at 8.30 P.M., have approved the Un-Audited Financial Results for the quarter ended 31st December, 2019.

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith the following:

1. Un-Audited Standalone Financial Results for the quarter ended 31st December, 2019.
2. Un-Audited Consolidated Financial Results for the Quarter ended 31st December, 2019.
3. Auditors' Report on the Standalone and Consolidated Financial Results for the Quarter.


Please Note that the opinion given by the Statutory Auditor in the Enclosed Audit Report is unmodified opinion.

We kindly request you to take the same on record.

Thanking You,
Yours Sincerely,
For **COMBAT DRUGS LIMITED**



Kumar Raghavan
**COMPANY SECRETARY &
COMPLIANCE OFFICER**



DECIPHER LABS LIMITED

(Formerly known as Combat Drugs Limited)

(CIN CL2320TG1986PLC006781)

Regd. off: 4th Floor , Plot No.94,Sagar Society , Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, email: info@combatdrugs.in, Ph: 040-48536100

Unaudited Consolidated Financial Results For the Quarter and Nine Months ended 31st December 2019

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Nine Months ended		Year ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	372.12	123.04	64.34	639.45	683.92	805.78
II. Other income	1.12	0.75	-	1.88	0.31	-
III. Total revenue (I + II)	373.24	123.79	64.34	641.33	684.23	805.78
IV. Expenses						
Cost of materials consumed	-	-	-	-	600.32	614.72
Purchase of Stock-in-Trade	-	16.80	-	61.85	-	-
Changes in inventories of finished goods and stock in trade	-	(0.01)	0.92	0.28	(21.41)	(22.42)
Depreciation and Amortisation	13.71	21.96	0.03	35.73	0.03	0.06
Employee benefits expense	276.26	65.89	27.87	402.47	36.73	109.73
Finance Charges	11.65	12.64	-	24.29	0.00	-
Other expenses	38.86	4.75	23.01	71.25	39.10	59.61
Total expenses	340.48	122.03	51.83	595.87	654.77	761.70
V. Profit/(Loss) before tax (III - IV)	32.76	1.76	12.51	45.46	29.46	44.08
VI. Tax expense:						
(1) Current tax	7.69	(0.32)	-	9.67	-	3.54
(2) Deferred tax	(1.00)	(3.04)	-	(4.04)	-	-
VII. Profit/(Loss) for the period (V-VI)	26.07	5.12	12.51	39.83	29.46	40.54
VIII. Other comprehensive income						
i) Items that will be reclassified to statement of profit and loss	-	-	-	-	-	-
Exchange differences on translating the financial statements of foreign Subsidiaries	2.33	(0.10)	0.55	2.30	0.50	0.10
IX. Total comprehensive income for the year	28.40	5.02	13.06	42.13	29.96	40.64
Paid Up Equity Share Capital (FV of Rs 10 each)	1010.00	800.00	800.00	1010.00	800.00	800.00
X. Earning per equity share						
(1) Basic	0.03	0.06	0.16	0.04	0.37	0.51
(2) Diluted	0.03	0.06	0.16	0.04	0.37	0.51

Notes

1) The operations of the Company relate to two segments viz., Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

Particulars	Quarter ended			Nine months ended		Year Ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Segment Revenue						
a) Manufacturing and Trading of Pharmaceutical drugs	0.00	17.00	36.45	64.10	656.34	629.66
b) Consultancy Services	373.24	106.79	27.89	577.23	27.89	176.12
Total Sales	373.24	123.79	64.34	641.33	684.23	805.78
Less: Inter Segment Revenue	-	-	-	-	-	-
Total Revenue from Operations	373.24	123.79	64.34	641.33	684.23	805.78
Segment Result (Profit Before Tax and Interest from each Segment)						
a) Manufacturing and Trading of Pharmaceutical drugs	-	0.20	10.77	1.90	27.72	20.65
b) Consultancy Services	32.76	1.56	1.74	43.56	1.74	23.43
Total	32.76	1.76	12.51	45.46	29.46	44.08
Less: Interest	-	-	-	-	-	-
Total Profit before tax	32.76	1.76	12.51	45.46	29.46	44.08
Capital employed (Segment assets - segment liabilities)						
Segment assets						
a) Manufacturing and trading of Pharmaceutical drugs	310.46	309.37	867.64	310.46	867.64	560.00
b) Consultancy Services	3245.94	286.55	28.05	3245.94	28.05	74.20
Total Assets	3556.40	595.92	895.68	3556.40	895.68	634.20
Segment liabilities						
a) Manufacturing and trading of Pharmaceutical drugs	55.07	81.01	655.62	55.07	655.62	334.11
b) Consultancy Services	2371.16	253.47	28.04	2371.16	28.04	47.48
Total Liabilities	2426.23	334.48	683.66	2426.23	683.66	381.59

2) The above results for the Quarter and Nine months ended 31st December 2019 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 14.02.2020.

3) The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4) During the quarter, the Company has invested in Decipher Software Solutions LLC, USA on 20.12.2019 and accordingly the above results include the financial results of Decipher Software Solutions LLC from 20.12.2019 to 31.12.2019. Hence, previous year/previous period figures are not comparable.

5) The above results include results of wholly owned subsidiaries

i) RA Labs Pte Ltd, Singapore ii) ICP Solutions Private Limited, India iii) Decipher Software Solutions LLC, USA

6) The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

7) The Group has adopted Ind AS 116, effective April 1, 2019 and applied the standard to its leases, retrospectively with the cumulative effect of initially applying the standard, recognised on the date of initial application (1st April 2019). Accordingly, the company has not restated comparative information, instead, the cumulative effect of initially applying this standard has been recognised as an adjustment to the opening balance of retained earnings as on 1st April 2019. The Company has adopted Ind AS 116 using the cumulative effect method of transitioning.

8) Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on behalf of the Board

Sushant Mohan Lal

Sushant Mohan Lal
Director
DIN: 01227151

Place: Hyderabad
Date: 14.02.2020

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher Labs Limited
(Formerly Known as Combat Drugs Limited)

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Decipher Labs Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended 31st December, 2019 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
ICP Solutions Private Limited, India
RA Labs Pte Ltd, Singapore
Decipher Software Solutions LLC, United States of America




5. Based on our review conducted, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The consolidated unaudited financial results include the interim financial results of the subsidiary ie RA Labs Pte Ltd, Singapore whose interim financial results/information reflects total revenue of Rs. Nil and Rs. Nil , total net loss after tax of Rs. 2.36 lakhs and Rs.3.58 lakhs and total comprehensive loss of Rs.2.36 lakhs and Rs.3.58 lakhs for the quarter ended December 31, 2019 and for the period from April 01, 2019 to December 31, 2019 respectively, which are certified by the management. According to the information and explanations given to us by the Management, these interim financial results and other financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

7. We did not review the interim financial results of the subsidiary, Decipher Software Solutions LLC, United States of America included in the consolidated unaudited financial results, whose interim financial results reflects total revenues of Rs. 238.37 lakhs, total net profit after tax of Rs.22.79 Lakhs, total comprehensive profit of Rs.22.79 lakhs for the quarter ended December 31, 2019 respectively as considered in the consolidated unaudited financial results. The interim financial results of the subsidiary has are reviewed by the other auditor whose report has been furnished to us by the Management, and our conclusion on the Statement in so far as it relates to the amounts and disclosures included in respect of the subsidiary, is based solely on the report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.0001255)




Y.Lakshmi Nagarathnam
Partner

M.No: 212926

UDIN: 20212926AAAAAZ6654

Place: Hyderabad

Date: 14th February, 2020



DECIPHER LABS LIMITED*(Formerly known as Combat Drugs Limited)***(CIN CL23230TG1986PLC006781)**

Regd.off: 4th Floor , Plot No.94,Sagar Society , Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034

URL: www.combatdrugs.in, email: info@combatdrugs.in, Ph: 040-48536100

Statement of Unaudited Standalone Financial Results For the Quarter and Nine Months ended 31st December, 2019

All amounts in ₹ Lakhs, unless otherwise stated

Particulars	Quarter ended			Nine Months ended		Year ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I. Revenue from operations	28.56	38.51	36.47	128.13	655.37	678.11
II. Other income	0.04	0.48	-	0.94	0.31	0.88
III. Total revenue (I + II)	28.60	38.99	36.47	129.07	655.68	678.98
IV. Expenses						
Cost of materials consumed	-	-	-	-	600.32	614.72
Purchase of Stock-in-trade	-	16.80	-	61.85	-	-
Changes in inventories of finished goods and stock in trade	-	(0.01)	0.92	0.28	(21.41)	(22.42)
Employee benefits expense	7.96	7.99	0.03	23.83	12.79	16.68
Depreciation and Amortisation expense	0.06	0.06	3.94	0.18	0.03	0.06
Other expenses	17.77	4.52	19.63	27.81	33.86	32.25
Total expenses	25.79	29.36	24.52	113.95	625.59	641.29
V. Profit before tax (III - IV)	2.81	9.63	11.95	15.12	30.09	37.69
VI. Tax expense:						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	(0.03)	0.01	-	(0.02)	-	0.01
VII. Profit/(Loss) for the period (V-VI)	2.84	9.62	11.95	15.14	30.09	37.68
VIII. Other comprehensive income						
IX. Total comprehensive income for the year	2.84	9.62	11.95	15.14	30.09	37.68
Paid Up Equity Share Capital (FV of Rs 10 each)	1,010.00	800.00	800.00	1,010.00	800.00	800.00
X. Earning per equity share						
(1) Basic	0.04	0.12	0.15	0.19	0.38	0.47
(2) Diluted	0.04	0.12	0.15	0.19	0.38	0.47

Notes

1) The above results for the quarter and Nine Months ended 31st December 2019 were reviewed by the Audit Committee and approved by the

Board of Directors of the Company at their meeting held on 14.02.2020. The Statutory Auditors have expressed an unmodified audit opinion.

2) The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 and SEBI circular dated 5 July, 2016.

3) The Company has only one operating segment as per the requirements of Ind AS 108 "Operating Segments".

4) Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.



For and on behalf of the Board

Sushant Mohan Lal

Director

DIN: 01227151

Place: Hyderabad

Date: 14.02.2020

M. ANANDAM & CO.,
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the
Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015**

**Review Report to The Board of Directors
Decipher Labs Limited**
(Formerly Known as Combat Drugs Limited)

We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Decipher Labs Limited** for the quarter and nine months ended 31st December, 2019. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M.Anandam & Co.,
Chartered Accountants
(Firm Regn.No.000125S)

Y. Lakshmi Nagaratnam

Y.Lakshmi Nagaratnam
Partner

Membership Number: 212926

UDIN: 20212926AAAAAY7087

Place: Hyderabad

Date: 14th February, 2020

